Cargando…

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse

The pharmacological chaperone, isofagomine (IFG), enhances acid β-glucosidase (GCase) function by altering folding, trafficking, and activity in wild-type and Gaucher disease fibroblasts. The in vivo effects of IFG on GCase activity, its substrate levels, and phenotype were evaluated using a neurono...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Ying, Ran, Huimin, Liou, Benjamin, Quinn, Brian, Zamzow, Matt, Zhang, Wujuan, Bielawski, Jacek, Kitatani, Kazuyuki, Setchell, Kenneth D. R., Hannun, Yusuf A., Grabowski, Gregory A.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080394/ https://www.ncbi.nlm.nih.gov/pubmed/21533102 http://dx.doi.org/10.1371/journal.pone.0019037

Ejemplares similares

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease
por: Dai, Mei, et al.
Publicado: (2016)

Global gene expression profile progression in Gaucher disease mouse models
por: Xu, You-Hai, et al.
Publicado: (2011)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease
por: Sun, Ying, et al.
Publicado: (2013)

Specific saposin C deficiency: CNS impairment and acid β-glucosidase effects in the mouse
por: Sun, Ying, et al.
Publicado: (2010)

Activation of p38 Mitogen-Activated Protein Kinase in Gaucher’s Disease
por: Kitatani, Kazuyuki, et al.
Publicado: (2015)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
por: Sun, Ying, et al.
Publicado: (2020)

Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology
por: Sun, Ying, et al.
Publicado: (2015)

Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014)

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease
por: Peng, Yanyan, et al.
Publicado: (2021)

In Vivo and Ex Vivo Evaluation of L-Type Calcium Channel Blockers on Acid β-Glucosidase in Gaucher Disease Mouse Models
por: Sun, Ying, et al.
Publicado: (2009)

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
por: Narita, Aya, et al.
Publicado: (2016)

Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease
por: Zigdon, Hila, et al.
Publicado: (2015)

Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype
por: Liou, Benjamin, et al.
Publicado: (2019)

Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease
por: Mhanni, A.A., et al.
Publicado: (2015)

Correction: Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan
por: Koto, Yuta, et al.
Publicado: (2023)

In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
por: Ciana, Giovanni, et al.
Publicado: (2020)

Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report
por: Ceravolo, Ferdinando, et al.
Publicado: (2017)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
por: Collin-Histed, Tanya, et al.
Publicado: (2023)

Drosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
por: Cabasso, Or, et al.
Publicado: (2019)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
por: Nakanishi, Etsuro, et al.
Publicado: (2021)

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease
por: Donald, Aimee, et al.
Publicado: (2022)

Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
por: Messelodi, Daria, et al.
Publicado: (2023)

Viable Neuronopathic Gaucher Disease Model in Medaka (Oryzias latipes) Displays Axonal Accumulation of Alpha-Synuclein
por: Uemura, Norihito, et al.
Publicado: (2015)

Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
por: Degnan, Andrew J., et al.
Publicado: (2019)

Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitis
por: Melamed, Sharon, et al.
Publicado: (2020)

Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy
por: Boddupalli, Chandra Sekhar, et al.
Publicado: (2022)

A multifaceted evaluation of microgliosis and differential cellular dysregulation of mammalian target of rapamycin signaling in neuronopathic Gaucher disease
por: Zhang, Zhenting, et al.
Publicado: (2022)

The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects
por: Kim, Yoo-Mi, et al.
Publicado: (2020)

Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease
por: Srikanth, Manasa P., et al.
Publicado: (2020)

Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

Isofagomine inhibits multiple TcdB variants and protects mice from Clostridioides difficile induced mortality
por: Paparella, Ashleigh S., et al.
Publicado: (2023)

Pharmacological Chaperones and Coenzyme Q(10) Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease
por: de la Mata, Mario, et al.
Publicado: (2015)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

Bioactive sphingolipid profile in a xenograft mouse model of head and neck squamous cell carcinoma
por: Bai, Aiping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_41esreme905mvvdtrpi27ngnjm